Learnings from the latest PCSK9i results and and profiles of patients who may benefit the most: efficacy and safety of alirocumab in ODYSSEY OUTCOMES patients with diabetes

25 August 2018 (00:00 - 00:00)
Organised by:

ESC 365 is supported by

ESC 365 is supported by